Genetic profiling of breast tumors to develop new cancer tests
Analyzes genetic features of breast tumors from patients to develop molecular tests.
Plain-language title generated from the registry record
Registry title: Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
Key facts
- Where
- Borås, Halmstad, Helsingborg, Jönköping, Karlskrona, Kristianstad, Lund, Malmö, Uppsala, and Vaxjo, SwedenSee the 10 sites
Where in Sweden
- Södra Älvsborg HospitalBorås, SwedenTaking people
- Hallands Hospital HalmstadHalmstad, SwedenNo longer taking part
- Helsingborg hospitalHelsingborg, SwedenTaking people
- Kirurgiska klinikenJönköping, SwedenNo longer taking part
- Blekinge County HospitalKarlskrona, SwedenTaking people
- Central Hospital KristianstadKristianstad, SwedenTaking people
- Skåne University HospitalLund, SwedenTaking people
- Skåne University HospitalMalmö, SwedenTaking people
- Uppsala University HospitalUppsala, SwedenTaking people
- Central Hospital VäxjöVaxjo, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lund University
- Trial code
- NCT02306096
- Record updated
- 27 August 2026
- Original description
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level data will be analyzed in the context of patient information, clinicopathological variables, and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses will be performed in the future.Read full original descriptionShow less
SCAN-B: The Sweden Cancerome Analysis Network - Breast Initiative
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level data will be analyzed in the context of patient information, clinicopathological variables, and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses will be performed in the future.
Inclusion: suspicion or confirmed diagnosis of primary breast cancer; signed informed consent.
Exclusion: lack of signed informed consent.